1. Home
  2. Directory
  3. Michigan
  4. Detroit
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1235396607

DR. ELISSA KAY FORY M.D.
Prescription History 1235396607
Psychiatry & Neurology - Neurology in Detroit, MI

NPI Status: Active since May 21, 2008

Contact Information

2799 W GRAND BLVD # K-11
DETROIT, MI
ZIP 48202
Phone: (800) 653-6568
Fax: (313) 916-5117

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ELISSA KAY FORY M.D., an active Neurology specialist practicing in Detroit, MI. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 77 documented patient claims. Among these therapy options, the most frequently utilized medication is Donepezil Hcl, which accounts for 37 claims alone.

Medication Index

C
D
L
No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 26
30-Day Fills 37.0
Days Supply 1,110
MI State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills103.2
Peer Average Days Supply3,001
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 54.4% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $876.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.72

State Avg Cost Per Claim

$59.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Donepezil Hcl

Generic Formulation: Donepezil HclSpecialty: Neurology
Provider Metrics Summary
Total Claims 37
30-Day Fills 77.0
Days Supply 2,310
MI State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills80.3
Peer Average Days Supply2,349
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $776.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.99

State Avg Cost Per Claim

$17.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Neurology
Provider Metrics Summary
Total Claims 14
30-Day Fills 32.0
Days Supply 960
MI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills70.7
Peer Average Days Supply2,037
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.6% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $582.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.63

State Avg Cost Per Claim

$48.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ELISSA KAY FORY M.D. provides transparency into local medical care patterns within Detroit, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.